MHCS-II First Follow Up Abstract/Off Study Form (Form 62)

Subject ID# (preprinted)

- If the subject is active in the study, supply information at the time of the MHCS-II Follow Up visit.
- If the subject is <u>no longer active in the study</u> for any reason, supply information through the last clinic visit.

Subject Verification Info:		cation Info:	Date of enrollment (2); DOB (1); Sex (5);					
1.	Subject's status		 □ currently active in study→ GO TO 3 □ deceased→ GO TO 1a □ transferred to another clinic→ GO TO 2 □ withdrew from study→ GO TO 2 					
	1a.	Date of death:	- - - Month Day	 Year				
	1b.		Clinically Defined isease Not Meeting AI	DS Diagnos		<u>Cause</u> only one)	Secondary Caus (Check all that a	
		Liver Failure	-	DD Diugnot				
		Hemorrhage,						
		Other Blood	-					
		Cancer, Spec	ify					
		Trauma	•					
		Heart Disease	e					
		Renal Diseas	e					
		Non-AIDS R	elated Infections					
		Stroke						
		Other Primar Other Second	y (Specify) lary (Specify)					
	1c.	Was an autopsy p	performed?	🗆 Yes		No	🗖 Unknown	
	1d.	Was liver tissue of	obtained?	🗆 Yes		No	🗖 Unknown	
	1e.	Source of death in	nformation:					
2.	Date of	the subject's mos	t recent clinic visit.	- Month	 Day	- Year]]	
	2a.		ollment in MHCS-II nrollment in MHCS-II	$\Box \to GO$ $\Box \to GO$		n Page 8		

Year

3.	Date of MHCS-II Follow up visit.		- _	
		Month	Day	

4. On the last MHCS-II data form, the subject's hemophilia genetic defect was reported as:

REPORTED: (preprinted)

Is this currently accurate?	Yes $\rightarrow GO TO 5$
	No $\rightarrow GO TO 4a$

5.	Indicate all clotting factor products and
	blood components the subject has used
	since:

(Date of Enrollment-preprinted)

IF <u>ONLY</u> 'OTHER BLOOD COMPONENTS', GO TO 8

6. Approximately how many units of **factor concentrate** did the subject receive since the Enrollment visit?

6a. On what basis was the factor administered?

- 7. Approximately how many units of **cryoprecipitate** did the subject receive since the Enrollment visit? (If available, record total mls; if not, record # of bags)
- 8. During the years 1979 1984, please estimate the **average annual amount** of factor concentrate that the subject received.

- None \rightarrow GO TO 8 Recombinant Monoclonal High Purity Intermediate Purity Cryoprecipitate Other blood components (include whole blood, platelets, red cells, plasma)
- None $\rightarrow GO TO 7$ Units: _____ Unknown
- Both prophylactically and on demand Only on demand (for a bleed)

None		
Total mls:		
OR		
# of bags:		
Unknown		

□ None

- Less than 20,000 units/year
- 20,001 50,000 units/year
- \Box > 50,000 units/year
- □ Unknown
- □ NOT APPLICABLE (BORN AFTER 1984)

9.	Do your records contain more detailed information about the subject's factor use during the years 1979-1984? (<i>i.e. dose information by year</i>)		Yes No
10.	Since the Enrollment visit, did the subject receive an HBV vaccine?		Yes No Unknown
11.	On the last MHCS-II data form, the subject's H	HBV chro	onic carrier status was reported as:
	REPORTED: (preprinted) Is this currently accurate?		Yes \rightarrow <i>GO TO 12</i> No \rightarrow <i>GO TO 11a</i>
12.	Has the subject ever been vaccinated for hepatitis A?		Yes → year of first HAV vaccination No Unknown
13.	What is the subject's current HCV antibody status? If no test in the past 12 months, record 'unknown'.		Positive Negative Unknown
14.	What is the subject's HIV status?		Positive

What is the subject's HIV status? 14.

Negative \rightarrow *GO TO 16*

- 15. Since the Enrollment visit, was the subject \Box Yes diagnosed with any AIDS-defining \Box No \rightarrow GO TO 16 condition?
 - 15a. Indicate AIDS-defining illness(es) and the date it was diagnosed. *Bolded items are cancers to report at Q. 24.*

Month and Year		Month and Year
CD4 <200 cells/ μ L or <14% -	Mycobacterium avium (not only	
CMV (not liver, spleen, lymph) -	lungs, skin, cervical nodes)	-
Candidiasis of esophagus or lungs	Non-Hodgkin's Lymphoma	
Cervical cancer, invasive	(not T-cell or CNS Primary)	-
Coccidioidmycosis, extrapulmonary	Pneumocystis carinii pneumonia	
Cryptococcosis, extrapulmonary	(PCP)	-
Cryptosporidiosis with diarrhea	Pneumonia, recurrent bacterial	
for > 1 month	(more than once in 12 months)	-
Herpes simplex, ulcer for > 1 month $ - $ $ - $	Progressive multifocal	
Herpes simplex in lungs or esophagus	leukoencephalopathy (PML)	-
Histoplasmosis, extrapulmonary	Pulmonary tuberculosis	-
HIV encephalopathy/dementia	Salmonella septicemia, recurrent	-
Isosporiasis with diarrhea	Toxoplasmosis of the brain	-
for > 1 month	Wasting syndrome	
Kaposi's Sarcoma	(emaciation, "slim disease")	-
Lymphoid interstitial pneumonia (LIP)	Other multiple or recurrent	
or pulmonary lymphoid hyperplasia -	bacterial infections at least 2 in	
Lymphoma of the brain	a 2-year period	-
(CNS Primary)		

- 16. Since the Enrollment visit, has the subject been diagnosed with any of the following HCV-related conditions? For each one the subject has had, record the date of diagnosis. If the subject has not been diagnosed with any of these, choose 'NONE'. *Bolded items are cancers to report at Q. 24*.
 - □ NONE
 - \Box Jaundice, persistent > 1 month
 - □ Ascites (hepatic-related)
 - □ Hepatic encephalopathy
 - □ Esophageal varices
 - □ Bleeding esophageal varices
 - □ Hepatocellular carcinoma (hepatoma)
 - □ Mixed (Type II) cryoglobulinemia
 - □ Aplastic anemia
 - **D** Porphyria cutanea tarda
 - □ Membranoproliferative glomerulonephritis
 - Biopsy proven Cirrhosis
 - \square Other, Specify

Month and year

-
-
-
-
-
-
-
-
-
-
-
-

We'd like to know about treatments the subject received for HCV since the Enrollment visit. Some brand names of HCV drugs are:

	in ugo un	•Standard interferon alone = <i>Intron</i> •Ribavirin = <i>Rebetol or Virazole</i> •Standard interferon and ribavirin t •Pegylated interferon = <i>PEG-Introp</i>	ogether	= Rebetron
17.		ne subject receive any treatment for since the Enrollment visit?		Yes No $\rightarrow GO TO 22$
18.		ne subject treated at the same time tandard interferon and ribavirin?		Yes No $\rightarrow GO TO 19$
	18a.	What brand was used?		Rebetron Other:
	18b.	When did use begin?	 Month	- Year
	18c.	Is the subject currently using it?		Yes→ <i>GO TO 19</i> No
	18d.	Why is the subject no longer using it?		Experienced side effects and stopped use early. Completed prescribed treatment.
19.		ne subject treated with <i>standard</i> ron <u>without</u> ribavirin?		Yes No $\rightarrow GO TO 20$
	19a.	What brand was used?		Intron Roferon Infergen Other:
	19b.	When did use begin?	 Month	_ - Year
	19c.	Is the subject currently using it?		Yes→ <i>GO TO 20</i> No
	19d.	Why is the subject no longer using it?		Experienced side effects and stopped use early. Completed prescribed treatment.

20.		he subject treated at the same time begylated interferon and ribavirin?		Yes No $\rightarrow GO TO 21$
	20a.	What brand was used? Indicate brands of both drugs.		PEG-Intron Pegasys Rebetol Virazole Other:
	20b.	When did use begin?	 Month	_ - Year
	20c.	Is the subject currently using it?		Yes→ <i>GO TO 21</i> No
	20d.	Why is the subject no longer using it?		Experienced side effects and stopped use early. Completed prescribed treatment
21.		he subject treated with <i>pegylated</i> eron <u>without</u> ribavirin?		Yes No $\rightarrow GO TO 22$
	21a.	What brand was used?		PEG-Intron Pegasys Other:
	21b.	When did use begin?	 Month	_ - Year
	21c.	Is the subject currently using it?		Yes→ <i>GO TO 22</i> No
	21d.	Why is the subject no longer using it?		Experienced side effects and stopped use early. Completed prescribed treatment.
22.		the Enrollment visit, has the subject liver biopsy?		Yes \rightarrow SEND PATH REPORT(S) AND SPECIMEN No \rightarrow GO TO 23
	22a.	What was the reason for the biopsy?		Clinical decision making Eligibility for clinical trial Other:
23.		ne subject <u>ever</u> been considered for or ated for a liver transplant?		Yes, formally evaluated by a transplant team $\rightarrow GO$ <i>TO 23a</i> Yes, considered but not formally evaluated by a transplant team $\rightarrow GO$ <i>TO 24</i>
				No, not considered or evaluated $\rightarrow GO TO 24$ Unknown $\rightarrow GO TO 24$

	23a.		as the subject received a liver ansplant?		Yes $\rightarrow \underline{\ } $ - $ \underline{\ } $ - $ \underline{\ } $ Month Year of transplant
					No, but on the eligibility list No, not currently on eligibility list
24.	been	diag <i>to in</i>	Enrollment visit, has the subject nosed with any type of cancer? <i>Be</i> <i>clude those cancers you listed at</i> 6.		Yes \rightarrow SEND PATH REPORT(S) AND SPECIMEN No \rightarrow GO TO 25
Cance	r #1	a.	Primary site		
		b.	Туре	Histo	ologic subtype
		c.	Is this cancer localized to the		Localized
			primary site or metastatic?		Metastatic
		d.	Diagnosis date		
				Mon	th Year
Cance	r #2	a.	Primary site		
		b.	Туре	Histo	ologic subtype
		c.	Is this cancer localized to the		Localized
			primary site or metastatic?		Metastatic
		d.	Diagnosis date	 Mont	- th Year
25. I	Has the	e sub	ject had a GI bleed, gastrointestinal		NO→ <i>GO TO 26</i>
			or gastrointestinal obstruction		Yes, GI bleed
			ince the Enrollment visit? (Check		Yes, gastrointestinal perforation
	all tha	it app	oly)		Yes, gastrointestinal obstruction (stenosis)
4			you sent in an Upper GI		Yes
		Supp	lement Form?		$No \rightarrow COMPLETE THE UPPER GI SUPPLEMENT FOR THIS SUBJECT.$
26.	Date	this	form completed		

Off Study Additional Questions (For subjects no longer active in MHCS-II)

27.	estimat	g the years 1979 - 1984, please te the average annual amount of concentrate that the subject received.		None Less than 20,000 units/year 20,001 - 50,000 units/year > 50,000 units/year Unknown NOT APPLICABLE (BORN AFTER 1984)
28.	informa during	ar records contain more detailed ation about the subject's factor use the years 1979-1984? ose information by year)		Yes No
29.	Has the hepatit	e subject ever been <u>vaccinated</u> against		Yes year of first HAV vaccination
	перани	18 A /		No Unknown
30.		e subject <u>ever</u> been considered for or		Yes, formally evaluated by a transplant team $\rightarrow GO$
	evaluat	ted for a liver transplant?		<i>TO 30a</i> Yes, considered but not formally evaluated by a transplant team $\rightarrow GO TO 31$
				No, not considered or evaluated $\rightarrow GO \ TO \ 31$ Unknown $\rightarrow GO \ TO \ 31$
	30a.	Has the subject received a liver transplant?		Yes $\rightarrow \ $ MonthYear of transplant
				No, but on the eligibility list No, not currently on eligibility list
31.	Date th	nis form completed	 Month	